CDSCO panel tells JnJ to submit clarification for weight based calculated fixed dose of Teclistamab

Published On 2023-08-23 07:24 GMT   |   Update On 2023-08-23 07:24 GMT
Advertisement

Based on the proposal presented by drug major Johnson & Johnson for the protocol amendment of the anticancer drug Teclistamab, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined that the firm should submit clarification for a weight-based calculated fixed dose of the anticancer drug Teclistamab in light of earlier trials along with other regulatory approvals for review of the committee.

This came after Johnson & Johnson presented its proposal for protocol amendment vide protocol No.64007957MMY3006, amendment 1, dated 16 Feb 2023 before the committee.

For more details, check out the link given below:

Submit Clarification For Weight-Based Calculated Fixed Dose: CDSCO Panel Tells J&J Over Teclistamab



Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News